Madjar, Weissberg these patients remain asymptomatic, and left sided pleural or pulmonary nodules may be discovered many years after the episode of trauma. Pulmonary nodules are often malignant, and it is commonly accepted that they should be considered malignant unless proven otherwise. Alertness to the possibility of thoracic splenosis can lead to confirmation of the diagnosis by the use of radionuclide scanning, and so prevent unnecessary thoracotomy and rendering the patient asplenic.
Abstract
Background -Nedocromil sodium, a nonsteroidal anti-inflammatory drug, is effective in the treatment of asthma. Its efficacy in the treatment of chronic obstructive pulmonary disease (COPD) has not been investigated. Methods -Fifty four non-allergic patients with COPD were randomised to 10 weeks of treatment with placebo or nedocromil sodium (4 x 8 mg/day) in a double blind study. Results -Nedocromil sodium treatment had no effect on airway responsiveness to histamine, methacholine, and adenosine-5'-monophosphate, pulmonary function, and symptom scores. Both patients and clinicians favoured treatment with nedocromil sodium, however, and the number ofdropouts ( of FEVy from baseline (PC20) <8 mg/ml; (4) no upper respiratory tract infection or exacerbation during six weeks before the start of the study. Patients with asthmatic attacks and wheeze were excluded. The study was approved by the hospital medical ethics committee and all subjects gave their written informed consent.
STUDY DESIGN
The study comprised a two week single blind placebo baseline, a 10 week double blind active treatment, and a 2 week placebo washout period. Inhaled corticosteroids were stopped two weeks before the start of the study. (table) . Fifteen patients in the placebo group and 21 in the treatment group were taking inhaled corticosteroids before the study (mean daily dose <700 1ig in each group (p>005)). Six patients withdrew during placebo administration and two during nedocromil sodium (p<0 05). During the washout period one patient was withdrawn after placebo and one after nedocromil sodium, all because of an exacerbation of their airways disease (figure).
FEV, (% predicted), morning PEF, evening PEF, diurnal peak flow variation, PC20 histamine, PC20 methacholine, PC20AMP, and all diary card symptom scores were similar for both placebo and nedocromil sodium groups. Taking use of corticosteroids before the treatment as covariable, there was no significant effect on these parameters.
Treatment was considered at least slightly effective in 59% of the patients receiving nedocromil sodium and in 43% of those receiving placebo (p>0 05), whereas the clinician (JW de J) considered the treatment at least slightly effective in 63% ofthose on nedocromil sodium and 24% of those on placebo (p<001). Side effects during nedocromil sodium and placebo were negligible. Discussion This is the first study to investigate the effects of nedocromil sodium in non-allergic patients with COPD. Following 10 weeks of treatment Weeks with nedocromil sodium and placebo there were only two treatment differences in favour of nedocromil sodium: the rate of withdrawals, all due to exacerbations, was significantly lower during treatment with nedocromil sodium, whereas clinician opinion of treatment efficacy significantly favoured nedocromil sodium.
There are several explanations why treatment with nedocromil sodium in our patients with COPD failed to improve clinical parameters. It is possible that nedocromil sodium is not a potent anti-inflammatory agent in this patient group; however, if nedocromil sodium is effective the duration of treatment may have been too short, as has been suggested for other anti-inflammatory agents.4 The type of airway inflammation, which is different in asthmatics5 who generally respond better to anti-inflammatory medication,6 may also play a part.
Instead of symptom scores, lung function, and airway responsiveness, other clinical parameters such as quality of life, decline in pulmonary function, or number and duration of exacerbations may be necessary to measure treatment efficacy in COPD.7 In this perspective our patients showed, in the short period of follow up, significantly fewer exacerbations when treated with nedocromil sodium. However, at the expense of treatment with nedocromil sodium, the higher withdrawal rate in the placebo group leads to selection bias, thus underestimating differences between placebo and nedocromil sodium treatment.
In conclusion, 10 weeks of treatment with a high daily dosage of nedocromil sodium did not improve pulmonary function, airway responsiveness, and clinical symptoms. The number of withdrawals, all due to exacerbations, was significantly greater in the placebo group than in the nedocromil sodium group. Longer trials will be necessary to determine whether nedocromil sodium reduces the frequency of exacerbations and the decrease in pulmonary function, eventually leading to a better quality of life in patients with COPD. 
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